Nektar Therapeutics (NKTR)
XMEX 
Summary
NKTR Chart
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 64.5% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
The consensus price target hints at a 62.8% upside potential for Nektar (NKTR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets
Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Dermatitis met endpoints, validating NKTR's approach and boosting confidence in its platform's clinical potential. NKTR's pipeline includes rezpegaldesleukin for other indications, and NKTR-255 for cancer, addressing significant unmet medical needs.
Nektar Therapeutics (NKTR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nektar Therapeutics ever had a stock split?
Nektar Therapeutics Profile
| Biotechnology Industry | Healthcare Sector | Howard W. Robin CEO | XMEX Exchange | US6402683063 ISIN |
| US Country | 61 Employees | - Last Dividend | 9 Jun 2025 Last Split | 3 May 1994 IPO Date |
Overview
Nektar Therapeutics is a prominent biopharmaceutical company specialized in the discovery and development of innovative therapies aimed at selectively modulating the immune system. With a primary focus on treating autoimmune disorders and chronic inflammatory conditions, Nektar Therapeutics leverages its expertise to create treatments that restore balance to the immune system. Operating both within the United States and internationally, the company's research and development efforts have led to the creation of a diverse pipeline of therapeutic candidates. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California, and maintains collaborative agreements with a range of leading pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, and Pfizer Inc., among others. This extensive network of collaborations underlines the company's commitment to advancing healthcare through innovation.
Products and Services
- NKTR-358: A pioneering therapeutic asset aimed at stimulating regulatory T (Treg) cells. This treatment is designed to correct the immune imbalance that underlies autoimmune diseases and chronic inflammatory conditions, representing a novel approach in the management of these disorders.
- PEG-CSF1: An engineered polyethylene glycol (PEG) modified hematopoietic colony-stimulating factor protein. PEG-CSF1 selectively modulates inflammation resolution processes and has broad applications across various therapeutic indications, including both acute and chronic inflammation. This versatility underscores its potential in addressing multiple health conditions.
- Tumor Necrosis Factor (TNF) Receptor Type II (TNFR2) Agonist Asset: A bivalent antibody molecule designed to selectively stimulate TNFR2 receptor activity. This asset avoids modulation of TNFR1 signaling, offering a targeted approach to stimulating the immune response in a way that could benefit patients with certain conditions.
- NKTR-255: An IL-15 receptor agonist that aims to enhance the body's natural cancer-fighting abilities. By boosting the immune system, NKTR-255 represents a promising tool in the fight against cancer, adding to the company's diverse portfolio of innovative therapies.
Contact Information
